On Friday, Werewolf Therapeutics Inc (NASDAQ: HOWL) was -8.29% drop from the session before settling in for the closing price of $1.93. A 52-week range for HOWL has been $1.66 – $8.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 5.40% over the last five years. When this article was written, the company’s average yearly earnings per share was at -46.19%. With a float of $32.70 million, this company’s outstanding shares have now reached $39.11 million.
The firm has a total of 47 workers. Let’s measure their productivity. In terms of profitability, gross margin is 59.3%, operating margin of -1955.35%, and the pretax margin is -1834.55%.
Werewolf Therapeutics Inc (HOWL) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Werewolf Therapeutics Inc stocks. The insider ownership of Werewolf Therapeutics Inc is 26.61%, while institutional ownership is 56.77%.
Werewolf Therapeutics Inc (HOWL) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.33 earnings per share (EPS) during the time that was better than consensus figure (set at -0.41) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -46.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.90% during the next five years compared to -13.31% drop over the previous five years of trading.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Trading Performance Indicators
You can see what Werewolf Therapeutics Inc (HOWL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.50, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Werewolf Therapeutics Inc (HOWL)
Analysing the last 5-days average volume posted by the [Werewolf Therapeutics Inc, HOWL], we can find that recorded value of 0.63 million was better than the volume posted last year of 0.38 million. As of the previous 9 days, the stock’s Stochastic %D was 4.07%. Additionally, its Average True Range was 0.25.
During the past 100 days, Werewolf Therapeutics Inc’s (HOWL) raw stochastic average was set at 4.37%, which indicates a significant increase from 1.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.13% in the past 14 days, which was lower than the 113.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2674, while its 200-day Moving Average is $3.8959. Now, the first resistance to watch is $1.9083. This is followed by the second major resistance level at $2.0467. The third major resistance level sits at $2.1233. If the price goes on to break the first support level at $1.6933, it is likely to go to the next support level at $1.6167. Now, if the price goes above the second support level, the third support stands at $1.4783.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Key Stats
There are 44,563K outstanding shares of the company, which has a market capitalization of 72.34 million. As of now, sales total 19,940 K while income totals -37,370 K. Its latest quarter income was 1,140 K while its last quarter net income were -17,250 K.
